About Giten

Giten is currently the Community and Policy Project Manager at amfAR’s TREAT Asia program in Bangkok, Thailand.  He has been working on improving hepatitis C treatment access and advocating for price reductions in South and South East Asia in partnership with regional and national community networks.  Giten also has been providing training to national PLHIV and PWID networks on hepatitis C treatment, access issues and direct-acting antivirals and their use with antiretroviral therapy. His involvement in regional advocacy for hepatitis C treatment access has included efforts to engage with global stakeholders, including innovator and generic pharmaceutical companies to address price- and non-price barriers. He was also profiled as a Change Maker for hepatitis C by the Economist Intelligence Unit in 2016.

This speaker will be presenting at the following session(s)

  • Treatment interventions

    Parallel workshop

    Day: 2 November

    Time: 11:30


    • The impact of generics in scaling up treatment.
    • Dr. Saeed Hamid, The Aga Khan University
    • Treatment in the private vs public sector.
    • Giten Khwairakpam, amfAR TREAT Asia
    • What price for what drug: is there a science to it?
    • Dr. Andrew Hill, Liverpool University
    • Decentralization and ECHO.

    Session objectives:

    • Highlight the impact various factors have had in significantly up scaling treatment, particularly in the LMIC.
    • Identify what treatment intervention strategy would work best in their own environments.